OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; o...
While TSMC has exited the GaN space both VIS and GF have licensed TSMC's 650 and 80V technology. We tend to see GF as more likely to realize greater benefits if GaN demand indeed grows at an accelerated pace, given GF's pre-existing efforts in the space, which TSMC's IP only builds upon. We'd also
Gran Tierra Energy has provided operational and financial updates for Q4 and FY 2025, published its 2025 reserves data and launched an exchange offer for its senior notes due 2029. The results and reserves were below expectations and failed to reach the low end of guidance. In our view, the exchange offer provides a good opportunity for the company to extend the bond duration while having more time to boost production and liquidity.
AUCTUS PUBLICATIONS ________________________________________ Arrow Exploration (AXL LN/CN)C; Target price of £0.40 per share: High production on low decline at Mateguafa – The M-8 well has been brought onstream in the C9 formation (30 ft of oil pay) at 230 bbl/d gross (115 bbl/d net) on a 28/128 choke with 78% water cut. The three C7 intervals did not flow commercial hydrocarbons. The well also encountered 12 ft of net pay in the Gacheta. Although M‑8 is the smallest contributor to field output,...
We would also point out that to date, China has invested over $15B in its domestic quantum ecosystem, compared to just under $8B in the US (per QED-C State of Global Quantum Industry), once again highlighting the need for additional Federal funding of the US' quantum ecosystem.Given the vested inte
Figure 1. 4Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusNote: 4Q revenue guide in the range of $56-$59B.Meta delivered strong 4Q results. Revenue in the quarter reached $59.9B (+23.8% Y/Y), ahead of consensus of $58.4B (+20.8% Y/Y) by ~3%. Revenue was well above the high
In this first take following tonight’s results, we focus on: 1. Jaw-dropping revenue acceleration trumps heavy investment, easily 2. Ad growth powered by impressions, with solid pricing too 3. 2026 expense guide well above consensus but operating income still growing 4. A wide range for 2026 capex guidance but still above Street
After a string of multi-GW contracts and capex announcements, the attractiveness of cloud AI returns remains a hot question amongst investors. In this report, we build a simple framework to answer that question. We estimate Cloud AI returns from CSP disclosures and what we know about large real-world contracts, and benchmark them against what we know about the economics of traditional cloud.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.